Adaptive Biotechnologies Launches Assay Enhancements to Increase clonoSEQ® Sensitivity for Clinical MRD Detection in Diffuse Large B-Cell Lymphoma
Portfolio Pulse from
Adaptive Biotechnologies has launched an enhanced version of its clonoSEQ assay, increasing sensitivity for detecting measurable residual disease in diffuse large B-cell lymphoma. The assay is approved by New York State's CLEP and is the only DLBCL MRD assay covered by Medicare.
March 11, 2025 | 12:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Adaptive Biotechnologies has launched an enhanced clonoSEQ assay for DLBCL, increasing sensitivity 7-fold. This product is approved by NY's CLEP and covered by Medicare, potentially boosting its market adoption.
The launch of the enhanced clonoSEQ assay, with increased sensitivity and regulatory approval, positions Adaptive Biotechnologies favorably in the market. The Medicare coverage further supports potential adoption, likely leading to positive short-term stock movement.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100